The above in vivo and in vitro results demonstrate that C3G has therapeutic effects on CIA and RA and suggest that C3G may exert its therapeutic effect by increasing the proportion of Treg cells and their IL-10 secretion and decreasing RASF proliferation as well as proinflammatory cytokine production. This evidence concerns the gene IL10 and rheumatoid arthritis.